CORT

Corcept Therapeutics Inc Health Care Pharmaceutical Preparations Russell 3000

$81.12Close $8.6BMarket cap $32.15 – $123.5752-week range Nov 3, 2026Next report · after the close

Highlights

Strengths

Leading the market RS 80 · stronger than 80% of stocks over 12 months
Earnings growing EPS +24% year on year, faster than the quarter before (+302 pts)

Cautions

Not in an uptrend 5 of 8 trend conditions
Far from its high 34% below its 52-week high
Distribution down-day volume 2.3× up-day volume over 50 sessions
Results soon Nov 3, 2026, in 2 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Jul 29, 2026

Off 12-month high 34%

1wk 5.5% price change

1mo 29.6% price change

12-month return 12% market up 11% · its own up 2%

F-score 4 / 9 Weak

Altman Z 29.93 Low risk

P/E 86.3× price / earnings

PEG — P/E / EPS growth

P/B 13.3× price / book

Earnings yield 0.5% EBIT / enterprise value

Cheaper than 24% of the market · expensive

Revenue growth 13% year on year

EPS growth 24% latest quarter · +302 pts

Sales growth 32% latest quarter · +27 pts

ROE 15% return on equity

Free cash margin 19% $141.8M FCF

D/E — long-term debt / equity

Net debt / EBITDA -2.6× net cash

Interest cover —EBIT / interest

Piotroski tests

profitability slipped from last year
short-term liquidity weakened
issued more shares
gross margin narrowed
assets working less efficiently
profitable on its assets
generating cash from operations
profits backed by cash
reduced long-term debt

Trade setup

ATR% 7.0% $5.68 a day · 2×ATR $69.77

RS 80 / 99 vs the universe

Trend 5 / 8 under the 150/200-day, under the 50-day, over 25% off the high

Relative volume 1.2× vs 50-day average

Up/down volume 0.43 50 sessions

Implied move — no option chain · report Nov 3, 2026

Trend template · 5 of 8

Price above the 150 and 200-day averages: fails
150-day average above the 200-day: passes
200-day average rising for a month: passes
50-day average above the 150 and 200-day: passes
Price above the 50-day average: fails
At least 30% above the 52-week low: passes
Within 25% of the 52-week high: fails
RS rank 70 or higher: passes

Screen verdict

Did not qualify for any screen.

Warning signs

none flagged

No restatement or impairment
Equity positive
Interest covered
No material dilution
Profits tracking cash
Margins and revenue not shrinking

Last reported Jul 29, 2026

Last shock Oct 23, 2026-20% in one session2.6× volumeno filing matched-6% since

Financials

6 fiscal years · from filings

Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $761.4M +13% on FY2024

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology $99.7M -29% on FY2024

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $141.8M -28% on FY2024

Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology

Gross 98%
Net 13%
Free cash 19%

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 105.97m -9.2% since FY2020

	FY2020Dec 31, 2020	FY2021Dec 31, 2021	FY2022Dec 31, 2022	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Revenue	$353.9M	$366.0M	$401.9M	$482.4M	$675.0M	$761.4M
Gross margin	98%	99%	99%	99%	98%	98%
Operating income	$128.2M	$124.5M	$112.6M	$107.3M	$137.0M	$44.8M
Net income	$106.0M	$112.5M	$101.4M	$106.1M	$141.2M	$99.7M
Net margin	30%	31%	25%	22%	21%	13%
Earnings per share	$0.85	$0.89	$0.87	$0.95	$1.24	$0.83
Free cash flow	$150.7M	$167.4M	$119.9M	$126.5M	$196.1M	$141.8M
Free cash margin	43%	46%	30%	26%	29%	19%
Cash	$76.2M	$77.6M	$66.3M	$135.6M	$127.7M	$120.5M
Shareholders' equity	$523.3M	$375.8M	$501.8M	$506.7M	$679.6M	$647.8M
Shares outstanding	116.73m	105.94m	107.83m	103.41m	105.11m	105.97m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Jul 29, 2026	Quarterly ↗	Jun 30, 2026	29d
Apr 30, 2026	Quarterly ↗	Mar 31, 2026	30d
Feb 24, 2026	Annual ↗	Dec 31, 2025	55d
Nov 4, 2025	Quarterly ↗	Sep 30, 2025	35d
Jul 31, 2025	Quarterly ↗	Jun 30, 2025	31d
May 5, 2025	Quarterly ↗	Mar 31, 2025	35d
Feb 26, 2025	Annual ↗	Dec 31, 2024	57d
Oct 30, 2024	Quarterly ↗	Sep 30, 2024	30d
Jul 29, 2024	Quarterly ↗	Jun 30, 2024	29d
May 1, 2024	Quarterly ↗	Mar 31, 2024	31d
Feb 15, 2024	Annual ↗	Dec 31, 2023	46d
Nov 1, 2023	Quarterly ↗	Sep 30, 2023	32d

Current reports

Filed	Disclosed
Sep 23, 2026	Director or officer change · Regulation FD ↗
Jul 29, 2026	Results · Regulation FD ↗
Jun 17, 2026	Other events ↗
Jun 3, 2026	Other events ↗
May 28, 2026	Director or officer change · Shareholder vote ↗
Apr 30, 2026	Results · Regulation FD ↗
Mar 25, 2026	Other events ↗
Feb 24, 2026	Results · Regulation FD ↗
Feb 19, 2026	Other events ↗
Jan 22, 2026	Other events ↗
Dec 31, 2025	Other events ↗
Nov 4, 2025	Results · Regulation FD ↗